Twiggy can this..., page-20

"Apologies if I've totally misunderstood how this division is operated, but could you explain how it's funded if AHZ aren't the ones putting money into it?"
Anthony you probably are aware that Admedus Vaccines is a separate company with its own Board and shareholders. If you have a look at the notes to the annual financials for AHZ (Note 15 in the 2016 statements and note 13 in the Dec 17 statements) headed "Controlled Entities" it discloses that the cost to the company (Admedus) for a 72.8% share in Admedus Vaccines is $13m and hasn't changed since June '16. If we do advance funds to the Vaccine company then we get to own a larger share of it. Note 2 to the statements - Segment Reporting - reveals that the Immunotherapy company has segment assets of $4.79m most of which I assume would be intangible assets for IP and patents etc. but some of it is probably cash. It does appear that whilst we did advance a fair amount of cash previously we have not tipped any in for some time.